Journal
NATURE MEDICINE
Volume 19, Issue 12, Pages 1597-1608Publisher
NATURE PORTFOLIO
DOI: 10.1038/nm.3409
Keywords
-
Funding
- NIAID/US National Institutes of Health
- US Department of Health and Human Services [HHSN272200800045C]
- Bill & Melinda Gates Foundation [42387]
Ask authors/readers for more resources
Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available